Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: comparison with atenolol and propranolol

Satoh, N.; Suzuki, J.; Bessho, H.; Kitada, Y.; Narimatsu, A.; Tobe, A.

Japanese Journal of Pharmacology 54(2): 113-119


ISSN/ISBN: 0021-5198
PMID: 2077180
DOI: 10.1254/jjp.54.113
Accession: 007269353

Download citation:  

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Effects of betaxolol, a cardioselective .beta.-adrenoceptor antagonist, on cardiohemodynamics and coronary circulation were investigated in two kinds of anesthetized open-chest dog preparations in comparison with those of atenolol and propranolol. When administered intravenously, betaxolol, atenolol and propranolol produced dose-dependent decreases in the heart rate (HR), maximum left ventricular dP/dt ((+)dP/dt), cardiac output (CO) and mean arterial pressure (MAP). Although all three drugs were almost equipotent in decreasing HR, betaxolol was much less potent than atenolol and propranolol in decreasing (+)dP/dt. Betaxolol decreased the total peripheral resistance (TPR), whereas atenolol and propranolol increased it. In another series of experiments, when administered intravenously, betaxolol, atenolol and propranolol all produced a decrease in the myocardial oxygen consumption (M.ovrhdot.VO2) and an increase in the atrioventricular conduction time (AVCT). All three drugs were nearly equipotent in decreasing M.ovrhdot.VO2, although betaxolol was less potent than the other two drugs at higher doses (> 300 .mu.g/kg). Prolongation of AVCT with propranolol was stronger than those with betaxolol and atenolol. These results suggest that, unlike atenolol and propranolol, the decrease in TPR as well as .beta.1-adrenoceptor blockade may be responsible for both the hypotensive effect of betaxolol and the decrease in M.ovrhdot.VO2 with betaxolol. The result that the cardiodepressant effect of betaxolol was much less potent than those of atenolol and propranolol suggests that betaxolol would be more beneficial than the others in the treatment of ischemic heart disease.